Trials / Completed
CompletedNCT03628677
A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies
A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 75 (actual)
- Sponsor
- Arcus Biosciences, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1, multicenter, open-label, dose-escalation study to evaluate the safety, tolerability, PK, PD, and clinical activity of domvanalimab (AB154) as monotherapy and in combination with zimberelimab (AB122) in participants with advanced solid malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Domvanalimab | Domvanalimabis a fully human immunoglobulin G1 (IgG1) monoclonal antibody targeting human TIGIT |
| DRUG | Zimberelimab | Zimbererlimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1 |
Timeline
- Start date
- 2018-09-12
- Primary completion
- 2025-01-23
- Completion
- 2025-01-23
- First posted
- 2018-08-14
- Last updated
- 2025-02-04
Locations
10 sites across 2 countries: United States, Australia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03628677. Inclusion in this directory is not an endorsement.